These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 34198161)
1. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Wehrli M; Maus MV Curr Opin Pharmacol; 2021 Aug; 59():116-126. PubMed ID: 34198161 [TBL] [Abstract][Full Text] [Related]
3. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828 [TBL] [Abstract][Full Text] [Related]
4. How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors? Schoenfeld AJ; O'Cearbhaill RE Cancer J; 2021 Mar-Apr 01; 27(2):134-142. PubMed ID: 33750073 [TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
6. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
7. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Martinez M; Moon EK Front Immunol; 2019; 10():128. PubMed ID: 30804938 [TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. Hsu J; Yang Y; Gergis M; Bi X; Yi D; Gergis U Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):94-99. PubMed ID: 36537910 [TBL] [Abstract][Full Text] [Related]
10. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Zhang E; Gu J; Xu H Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591 [TBL] [Abstract][Full Text] [Related]
11. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138 [TBL] [Abstract][Full Text] [Related]
12. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review]. Fang Z; Han H; Liang L Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572 [TBL] [Abstract][Full Text] [Related]
14. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932 [TBL] [Abstract][Full Text] [Related]
15. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936 [TBL] [Abstract][Full Text] [Related]
16. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Hiltensperger M; Krackhardt AM Front Immunol; 2023; 14():1121030. PubMed ID: 36949949 [TBL] [Abstract][Full Text] [Related]
17. CAR-T Cell Therapy: Challenges and Optimization. Luo M; Zhang H; Zhu L; Xu Q; Gao Q Crit Rev Immunol; 2021; 41(1):77-87. PubMed ID: 33822526 [TBL] [Abstract][Full Text] [Related]
18. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors. Adachi K; Tamada K Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968 [TBL] [Abstract][Full Text] [Related]